Tanespimycin (17-AAG)

Name: Tanespimycin (17-AAG)
Brand: Selleck Chemicals
SKU: S1141
Rating: 5 (62 reviews)

For research use only.

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

62 publications

Tanespimycin (17-AAG) Chemical Structure

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 2.

Selleck's Tanespimycin (17-AAG) has been cited by 62 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Cancers (Basel), 2020, 7;12(4)

PubMed: 32272809 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Mol Cell, 2019, 75(4):823-834

PubMed: 31302001 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5043

PubMed: 31695040 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):737

PubMed: 31570706 ( click the link to review the publication )

Cells, 2019, 8(8)

PubMed: 31370342 ( click the link to review the publication )

Front Cell Dev Biol, 2019, 7:204

PubMed: 31608279 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:2050183

PubMed: 31178953 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29283

PubMed: 31595984 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(2):220-233

PubMed: 31516744 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5637

PubMed: 30948782 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(2):312-324

PubMed: 30745823 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 371:63-73

PubMed: 30953615 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):102

PubMed: 30678647 ( click the link to review the publication )

Exp Eye Res, 2019, 189:107821

PubMed: 31589841 ( click the link to review the publication )

J Natl Cancer Inst, 2018, 110(4):390-399

PubMed: 29202196 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(6):2199-2215

PubMed: 29975948 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):1051-1060

PubMed: 29440291 ( click the link to review the publication )
Mycoses, 2018, 61(11):853-856

PubMed: 29998564 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

EMBO J, 2017, 36(5):646-663

PubMed: 28093501 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(3):543-554

PubMed: 27592300 ( click the link to review the publication )

Sci Rep, 2017, 7(1):4546

PubMed: 28674407 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 329:282-292

PubMed: 28624441 ( click the link to review the publication )

Am J Transl Res, 2017, 9(11):4945-4953

PubMed: 29218092 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2219-2226

PubMed: 28458565 ( click the link to review the publication )

Cell, 2017, 170(5):845-859

PubMed: 28823557 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Nat Commun, 2016, 7:13122

PubMed: 27959342 ( click the link to review the publication )

Cancer Res, 2016, 76(4):965-73

PubMed: 26676744 ( click the link to review the publication )

Oncogene, 2016, 35(29):3854-3865

PubMed: 26657151 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Biochem J, 2016, 473(12):1733-44

PubMed: 27059856 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(17):14796-813

PubMed: 26142707 ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Mol Cancer, 2014, 15:30

PubMed: 24927996 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805 ( click the link to review the publication )

Exp Gerontol, 2014, 52:55-69

PubMed: 24486130 ( click the link to review the publication )

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629 ( click the link to review the publication )
Julius Maximilians Universit, 2014, Kumari G

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213 ( click the link to review the publication )

Mol Cell, 2013, 50(3):368-78

PubMed: 23583076 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801 ( click the link to review the publication )

Sci Transl Med, 2012, 4(120):120ra17

PubMed: 22277784 ( click the link to review the publication )

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003 ( click the link to review the publication )

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451 ( click the link to review the publication )

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234 ( click the link to review the publication )

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504 ( click the link to review the publication )

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Biological Activity

Description

Features

Displays very low toxicity toward normal cells.

Targets

HSP90 ^[1]
(Cell-free assay)

5 nM

In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	M2G1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPWT5ZKSzVyPUCuNFAxOzB\|IN88US=>	NX;OdI9vW0GQR1XS
IST-MEL1	Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojUTWM2OD1yLkCwNFQxPyEQvF2=	NFzaUIVUSU6JRWK=
NCI-SNU-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHhOJZKSzVyPUCuNFAzODdizszN	NYLwUFFPW0GQR1XS
FADU	NHvER4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXe3WZhbUUN3ME2wMlAxOjB7IN88US=>	Mn72V2FPT0WU
C32	NF:xV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1GwZWlEPTB;MD6wNFMxPCEQvF2=	NFO3[JNUSU6JRWK=
D-566MG	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PmeWlEPTB;MD6wNFM6KM7:TR?=	MlvXV2FPT0WU
LXF-289	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwMEC0NVkh\|ryP	M37JNnNCVkeHUh?=
HGC-27	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwMEC1NUDPxE1?	MV7TRW5ITVJ?
RPMI-7951	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\ITGlEPTB;MD6wNFcyPyEQvF2=	NVXCZ3NwW0GQR1XS
HSC-3	NF20bYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XxbWlEPTB;MD6wNFkzQSEQvF2=	NGDJ[IdUSU6JRWK=
MIA-PaCa-2	NEW0PZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\iTWM2OD1yLkCxNFA6KM7:TR?=	NWrlfHBzW0GQR1XS
KS-1	M4GxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMEGzOVUh\|ryP	M4L1RXNCVkeHUh?=
CAL-51	NV70eIpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XlbGlEPTB;MD6wNVQxPSEQvF2=	NEPqS4hUSU6JRWK=
MDA-MB-361	NH3tWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXwTWM2OD1yLkCxOFk2KM7:TR?=	M4nsV3NCVkeHUh?=
TI-73	NH;ReZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfQd4NKSzVyPUCuNFE4QTZizszN	M4C1O3NCVkeHUh?=
AGS	NU\XZ5NUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjGTWM2OD1yLkCxPVM5KM7:TR?=	Ml;OV2FPT0WU
NCI-H460	M174[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vwXmlEPTB;MD6wNVk4PCEQvF2=	NIfFUohUSU6JRWK=
A204	M{jWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fpS2lEPTB;MD6wNlI1QSEQvF2=	NX;jUXFHW0GQR1XS
CHL-1	M3fmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\td2pSUUN3ME2wMlAzOjVzIN88US=>	M3foXXNCVkeHUh?=
DU-4475	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwMEKyOlEh\|ryP	NUT2e2RsW0GQR1XS
CGTH-W-1	MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\5SmlEPTB;MD6wNlM1QSEQvF2=	MYLTRW5ITVJ?
HCC2218	Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\VRZp7UUN3ME2wMlAzPDl2IN88US=>	M{j4OXNCVkeHUh?=
A2780	NGnVc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DZUmlEPTB;MD6wNlU{OSEQvF2=	MnTZV2FPT0WU
NCI-H720	NHfOVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfWbG1FUUN3ME2wMlAzPTR4IN88US=>	NGHMcpFUSU6JRWK=
NCI-N87	Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMEK1PVMh\|ryP	M3vxWXNCVkeHUh?=
CHP-212	NH3HZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;jcGlEPTB;MD6wNlYzQCEQvF2=	NUjjbpUyW0GQR1XS
NCI-H23	MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7aTWM2OD1yLkCyOlY2KM7:TR?=	Mn\wV2FPT0WU
D-263MG	NY\yW\|F3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwMEK3PFYh\|ryP	NGXkSYtUSU6JRWK=
ME-180	MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMEK4PVEh\|ryP	M2npNnNCVkeHUh?=
SW982	MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETKUoNKSzVyPUCuNFI6QTlizszN	NYjpXoVwW0GQR1XS
OE19	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXrTWM2OD1yLkCzNFc4KM7:TR?=	NFLzc5BUSU6JRWK=
SK-LU-1	NGPyUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvUTWM2OD1yLkCzNFgzKM7:TR?=	NEi0SYVUSU6JRWK=
H4	NXfnSoxjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVf0RZpIUUN3ME2wMlA{ODlizszN	M4DPcXNCVkeHUh?=
HT-144	M3nFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXVTWM2OD1yLkCzNFk{KM7:TR?=	MlHzV2FPT0WU
SK-UT-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTBwMEOxO\|gh\|ryP	M2T5c3NCVkeHUh?=
D-336MG	M1;qV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF6yPYFKSzVyPUCuNFM{ODlizszN	NY\jWVF[W0GQR1XS
MDA-MB-175-VII	NEXHfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTme\|VKSzVyPUCuNFM{PTRizszN	MnTDV2FPT0WU
GAMG	M1qwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PTXmlEPTB;MD6wN\|Q{PSEQvF2=	MmHsV2FPT0WU
CP50-MEL-B	M3LQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwMEO0OUDPxE1?	MkfPV2FPT0WU
OVCAR-5	NVuyUmQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTBwMEO0PEDPxE1?	M1PZcXNCVkeHUh?=
SK-MES-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LqcGlEPTB;MD6wN\|YxPiEQvF2=	MXTTRW5ITVJ?
VM-CUB-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwMEO2OVch\|ryP	MmTpV2FPT0WU
WM-115	M{e5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PBd2lEPTB;MD6wN\|c3OiEQvF2=	NUSxSmN{W0GQR1XS
DSH1	M13adWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTBwMEO4NFch\|ryP	NHXyUWFUSU6JRWK=
Becker	NYP1bnNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoruTWM2OD1yLkCzPFg2KM7:TR?=	M3L2NHNCVkeHUh?=
SW962	M{jvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTuTWM2OD1yLkCzPVQ2KM7:TR?=	M1rT[3NCVkeHUh?=
TYK-nu	NX\JbYVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXNTWM2OD1yLkCzPVg2KM7:TR?=	MnLJV2FPT0WU
HO-1-N-1	NF3aS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4P3emlEPTB;MD6wOFAzOSEQvF2=	M3O3[HNCVkeHUh?=
T98G	NX65XIhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LXcmlEPTB;MD6wOFExOyEQvF2=	NHXQOIJUSU6JRWK=
ACN	NGX2XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUP5Xo52UUN3ME2wMlA1OTZ{IN88US=>	MVLTRW5ITVJ?
SW780	MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LtT2lEPTB;MD6wOFIxOyEQvF2=	MmXYV2FPT0WU
Detroit562	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4L6cWlEPTB;MD6wOFI{QSEQvF2=	MXzTRW5ITVJ?
BB49-HNC	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3S5bGlEPTB;MD6wOFI1OyEQvF2=	NVXFWG1MW0GQR1XS
HN	M{fHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TERmlEPTB;MD6wOFI4OiEQvF2=	M1v0OnNCVkeHUh?=
H9	NULMbmJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLhb4lKSzVyPUCuNFQ{PzFizszN	MofyV2FPT0WU
VA-ES-BJ	NFfMbZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HlcGlEPTB;MD6wOFQ1PyEQvF2=	NFOyOWlUSU6JRWK=
MEL-JUSO	NH7ZSmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTBwMES0O\|Uh\|ryP	NIPuRZFUSU6JRWK=
BT-474	M3HW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M32yS2lEPTB;MD6wOFUh\|ryP	MVTTRW5ITVJ?
CaR-1	NWXCV4xQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwMES1OFkh\|ryP	MmPVV2FPT0WU
PSN1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVH3O25rUUN3ME2wMlA1PjB\|IN88US=>	MoHBV2FPT0WU
KYSE-510	NXu1bohFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHwPHJKSzVyPUCuNFQ3PDlizszN	M3;ZTHNCVkeHUh?=
KP-4	NELpb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XyfWlEPTB;MD6wOFc2OyEQvF2=	M334bnNCVkeHUh?=
KYSE-410	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIC0fIJKSzVyPUCuNFQ4PzJizszN	MoXzV2FPT0WU
G-402	MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zsW2lEPTB;MD6wOFc5QSEQvF2=	M4fuXXNCVkeHUh?=
DOK	M3T3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1OxOWlEPTB;MD6wOFkxOiEQvF2=	NHzZfnpUSU6JRWK=
COR-L88	M1\BN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfKOYZKSzVyPUCuNFQ6OTJizszN	M2e3dnNCVkeHUh?=
SKG-IIIa	NUHBcYNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37pVWlEPTB;MD6wOFk5PiEQvF2=	M3LCVXNCVkeHUh?=
AN3-CA	MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXzTWM2OD1yLkC1JO69VQ>?	NVjrNW1FW0GQR1XS
SW48	NEDCeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jxWGlEPTB;MD6wOVA{QSEQvF2=	NXTENXNqW0GQR1XS
YKG-1	NVvRWFJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHIeYM1UUN3ME2wMlA2ODdzIN88US=>	NFHwdIhUSU6JRWK=
KYSE-150	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrleGdKSzVyPUCuNFUzOzVizszN	NXftN28xW0GQR1XS
HuO-3N1	MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGq2dGxKSzVyPUCuNFUzOzdizszN	MXPTRW5ITVJ?
LB1047-RCC	NGrpO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwMEWyPVYh\|ryP	MWnTRW5ITVJ?
NCI-H2030	NWn4RXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLuTWM2OD1yLkC1OFE1KM7:TR?=	M4fJXnNCVkeHUh?=
YH-13	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzLW2ZRUUN3ME2wMlA2PzJ{IN88US=>	M3\Z[XNCVkeHUh?=
5637	M1\0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwMEW3OEDPxE1?	M125c3NCVkeHUh?=
LOXIMVI	M3HCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwMEW4O\|Ih\|ryP	Mn;hV2FPT0WU
GT3TKB	M1TlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMEW5OFIh\|ryP	MoPWV2FPT0WU
TCCSUP	NEO3W4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXYTWM2OD1yLkC1PVY1KM7:TR?=	NVzYfZVrW0GQR1XS
EPLC-272H	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\CUI1kUUN3ME2wMlA3OjB3IN88US=>	MVvTRW5ITVJ?
LU-99A	NGPFWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HQdWlEPTB;MD6wOlI{PyEQvF2=	MkXUV2FPT0WU
NCI-H1755	MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3jTWM2OD1yLkC2N\|QyKM7:TR?=	MmDIV2FPT0WU
KM12	NFS3WHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TKSGlEPTB;MD6wOlM1QCEQvF2=	MX3TRW5ITVJ?
SF295	NEHZW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vDU2lEPTB;MD6wOlQ2OiEQvF2=	NFrPWoFUSU6JRWK=
MZ2-MEL	NXOzW5E6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvqTWM2OD1yLkC2OVU{KM7:TR?=	NYL1OndRW0GQR1XS
HEC-1	NHT0bYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjQTWM2OD1yLkC2OVg5KM7:TR?=	NIewbo9USU6JRWK=
SW684	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTBwME[1PVEh\|ryP	MVjTRW5ITVJ?
SF539	M1vqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwME[2PFEh\|ryP	MofFV2FPT0WU
GMS-10	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwME[2PVkh\|ryP	MX\TRW5ITVJ?
MV-4-11	M2\Z[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;FT4hKSzVyPUCuNFY5ODNizszN	NVzqXVNSW0GQR1XS
HT-29	MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPtV\|JUUUN3ME2wMlA3QTF7IN88US=>	MYDTRW5ITVJ?
23132-87	NV20cpdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFm4WpNKSzVyPUCuNFY6PSEQvF2=	NH[2bFFUSU6JRWK=
SW620	NFr1PWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfMdGtKSzVyPUCuNFcxOjZizszN	M4HFNnNCVkeHUh?=
HCC1806	NH;jcnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vCdGlEPTB;MD6wO\|E{OSEQvF2=	NV3BNHdiW0GQR1XS
Hs-578-T	Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{[2UmlEPTB;MD6wO\|IxQCEQvF2=	M1vqO3NCVkeHUh?=
A2058	NWDDWoY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLCTWM2OD1yLkC3NlI5KM7:TR?=	MY\TRW5ITVJ?
MEL-HO	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMEeyOVUh\|ryP	MYXTRW5ITVJ?
HCC2998	NFO3WZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M335V2lEPTB;MD6wO\|M1PyEQvF2=	MnXCV2FPT0WU
HuO9	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTNTWM2OD1yLkC3OVg6KM7:TR?=	MWnTRW5ITVJ?
CAL-39	NFXnVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4mwVWlEPTB;MD6wO\|c3PiEQvF2=	NUPLZXRwW0GQR1XS
M14	NHPEZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmG2TWM2OD1yLkC3PVE{KM7:TR?=	M3rTOHNCVkeHUh?=
BFTC-909	NVnxR\|dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVr2[mJCUUN3ME2wMlA4QTZ7IN88US=>	M1S2PHNCVkeHUh?=
TE-11	NWDhN2VST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nVcGlEPTB;MD6wO\|k6PiEQvF2=	M1;4VnNCVkeHUh?=
TGBC1TKB	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\HXmlEPTB;MD6wPFA1OyEQvF2=	M165S3NCVkeHUh?=
L-363	M3vWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwMEiyNFYh\|ryP	NHHrWG5USU6JRWK=
A431	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHiTWM2OD1yLkC4NlEh\|ryP	MXLTRW5ITVJ?
MKN45	MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLOWnpKSzVyPUCuNFgzOTlizszN	M133N3NCVkeHUh?=
HT-1080	NXjGVmhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TFfGlEPTB;MD6wPFQ{QSEQvF2=	M4LwVHNCVkeHUh?=
OVCAR-8	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMEi2NlIh\|ryP	MWfTRW5ITVJ?
LCLC-97TM1	MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHxSpdVUUN3ME2wMlA5PzJ6IN88US=>	M2HJfXNCVkeHUh?=
M059J	NULDb215T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnWPJVJUUN3ME2wMlA6ODJ5IN88US=>	M{\ZfXNCVkeHUh?=
SK-MEL-2	NWeybYg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHFZlV5UUN3ME2wMlA6ODZizszN	MWDTRW5ITVJ?
TE-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HJWGlEPTB;MD6wPVIxPCEQvF2=	NELEU3JUSU6JRWK=
KYSE-180	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwMEmyOlIh\|ryP	NFL5cIhUSU6JRWK=
D-247MG	MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jiOGlEPTB;MD6wPVQ2PSEQvF2=	M3OwdXNCVkeHUh?=
8-MG-BA	NXvGeIJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV:1bm1RUUN3ME2wMlA6PDd{IN88US=>	Mn7iV2FPT0WU
NCI-H1792	M{ewSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjMfplKSzVyPUCuNFk3OThizszN	M2rTcXNCVkeHUh?=
MCF7	M4qxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3z0[2lEPTB;MD6wPVY4PyEQvF2=	NUjRUYRbW0GQR1XS
NCI-H2122	NI[zOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUH3PIVUUUN3ME2wMlA6PzR3IN88US=>	M4L6RXNCVkeHUh?=
EFO-27	NYn2THUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmj2TWM2OD1yLkC5PVk4KM7:TR?=	NGPjSZNUSU6JRWK=
LB2241-RCC	NGPiVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2iyd2lEPTB;MD6xNFA2PCEQvF2=	NV:3UlJQW0GQR1XS
SN12C	NGHI[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTBwMUCxNFch\|ryP	NEjlNHNUSU6JRWK=
A498	M2PRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXf4emVlUUN3ME2wMlExOThizszN	NEDhS\|JUSU6JRWK=
PANC-03-27	M{jhRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTBwMUCyPFYh\|ryP	NXH5ZlNLW0GQR1XS
NCI-H1581	NGnQZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3X0[GlEPTB;MD6xNFI6KM7:TR?=	NUn5c4NTW0GQR1XS
U-87-MG	NXfuUJBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLNTWM2OD1yLkGwN\|A4KM7:TR?=	MX;TRW5ITVJ?
G-401	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY[4[VBlUUN3ME2wMlExOzV\|IN88US=>	NGfRVFBUSU6JRWK=
SiHa	MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTLSnJWUUN3ME2wMlExPDh4IN88US=>	MnXhV2FPT0WU
U251	NV;JPG9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rVUWlEPTB;MD6xNFUzPSEQvF2=	Mk\SV2FPT0WU
MMAC-SF	MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;pOWlEPTB;MD6xNFU{OSEQvF2=	MWLTRW5ITVJ?
BB65-RCC	NVPZNGI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV6zXWlqUUN3ME2wMlExPTV2IN88US=>	NV\lXnVIW0GQR1XS
NKM-1	NFHoRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\udm1KSzVyPUCuNVA3PjZizszN	M1vCe3NCVkeHUh?=
HD-MY-Z	NH3yT\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7lTWM2OD1yLkGwPFc{KM7:TR?=	Ml7zV2FPT0WU
TGBC11TKB	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmj5TWM2OD1yLkGwPVA{KM7:TR?=	M4\2TnNCVkeHUh?=
COLO-679	MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILNSZNKSzVyPUCuNVEzOTFizszN	NIPL[XlUSU6JRWK=
TE-8	M1O4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vpeGlEPTB;MD6xNVI3PCEQvF2=	NVTPO\|BwW0GQR1XS
SK-MEL-28	MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvQNYFKSzVyPUCuNVE{OjFizszN	NWHI[2h{W0GQR1XS
SH-4	NV6zR5F6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnzWVIzUUN3ME2wMlEyOzV4IN88US=>	NWLHOGVoW0GQR1XS
KALS-1	NYHvW2ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMUGzPVMh\|ryP	NHv0PZdUSU6JRWK=
RKO	M3Hj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF20[o1KSzVyPUCuNVE4PjRizszN	NGTsZXhUSU6JRWK=
OMC-1	NXPQS3c3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwMUG3PVch\|ryP	MkXaV2FPT0WU
BT-549	M{HDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mom1TWM2OD1yLkGxO\|k6KM7:TR?=	MVHTRW5ITVJ?
NCI-H28	NI\zUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwMUG4NVch\|ryP	NXrmSoFGW0GQR1XS
RXF393	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwMUG5PFIh\|ryP	NWjQZm11W0GQR1XS
COLO-829	NYT1[YVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLnTWM2OD1yLkGyNFA2KM7:TR?=	M3PITXNCVkeHUh?=
HMV-II	M3:zeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\DWGlEPTB;MD6xNlAzKM7:TR?=	MVLTRW5ITVJ?
SW1990	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELaemhKSzVyPUCuNVIyPTdizszN	MXnTRW5ITVJ?
NCI-H1437	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXuTWM2OD1yLkGyNVU4KM7:TR?=	MW\TRW5ITVJ?
SNB75	Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2L1dmlEPTB;MD6xNlE3QSEQvF2=	NUiySphuW0GQR1XS
EW-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmG0TWM2OD1yLkGyOlYyKM7:TR?=	MV3TRW5ITVJ?
SAS	Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLHOmJQUUN3ME2wMlEzPjlizszN	MXrTRW5ITVJ?
NCI-H1666	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkWxTWM2OD1yLkGyO\|c1KM7:TR?=	MWnTRW5ITVJ?
A375	M1j6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwMUK3O\|gh\|ryP	MlfEV2FPT0WU
CAMA-1	MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXNT4lKSzVyPUCuNVI6OjRizszN	NXW3OWQ3W0GQR1XS
HuP-T4	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXYWW41UUN3ME2wMlEzQTR\|IN88US=>	NGjDTmpUSU6JRWK=
NCI-H292	NGTrXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;RdFlKSzVyPUCuNVMyOSEQvF2=	NXXTXFdQW0GQR1XS
PC-14	NIfNSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDTT\|ZKSzVyPUCuNVMzOTFizszN	M1;2b3NCVkeHUh?=
BPH-1	MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXmPItTUUN3ME2wMlE{PDFizszN	NIjLSWlUSU6JRWK=
GAK	NFTZcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTZTWM2OD1yLkGzOVY4KM7:TR?=	MUXTRW5ITVJ?
VMRC-RCZ	Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mly2TWM2OD1yLkGzO\|YzKM7:TR?=	M33kSHNCVkeHUh?=
SK-MEL-24	NH25PHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7FcIdKSzVyPUCuNVM5PyEQvF2=	M4f0SHNCVkeHUh?=
LB831-BLC	NYmxOZVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFe0VpNKSzVyPUCuNVM5QDNizszN	MX\TRW5ITVJ?
NCI-H2452	NVy4Vod1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4O3XGlEPTB;MD6xN\|k2PiEQvF2=	M1nBTHNCVkeHUh?=
RT-112	NFzEXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\mTWM2OD1yLkG0NFM2KM7:TR?=	MWnTRW5ITVJ?
GP5d	NXfwTWZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTBwMUSxNFQh\|ryP	NVPOclJWW0GQR1XS
LC-2-ad	M4\t[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;0NWlEPTB;MD6xOFEzOSEQvF2=	MYXTRW5ITVJ?
MPP-89	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmroTWM2OD1yLkG0NVI2KM7:TR?=	M3[zbnNCVkeHUh?=
NUGC-3	NIHSOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGe2VZlKSzVyPUCuNVQ1PzhizszN	MkDIV2FPT0WU
GI-1	NW\WZXl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXR[WdKSzVyPUCuNVQ2PThizszN	NUfC[JVnW0GQR1XS
HCC1419	NILqVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;zVGlEPTB;MD6xOFU4PiEQvF2=	MleyV2FPT0WU
SW1573	M2S0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELFWG9KSzVyPUCuNVQ4PThizszN	M1jD[3NCVkeHUh?=
NCI-H2347	M2i4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3QOY5KSzVyPUCuNVQ5OzlizszN	MYrTRW5ITVJ?
Mewo	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\lZoRUUUN3ME2wMlE1QDh7IN88US=>	NWTPW\|c5W0GQR1XS
639-V	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMUWwNVMh\|ryP	NHny[INUSU6JRWK=
AsPC-1	NYT3RY5jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMUWyNlUh\|ryP	MnO1V2FPT0WU
NCI-H1648	NIjmVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLsRmhKSzVyPUCuNVUzOzJizszN	NVrmSIt[W0GQR1XS
786-0	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jnfGlEPTB;MD6xOVM5OSEQvF2=	NXfYVWtxW0GQR1XS
ETK-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LZemlEPTB;MD6xOVkh\|ryP	Ml;5V2FPT0WU
BxPC-3	NULTVI1bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfLT4lvUUN3ME2wMlE2QTZ4IN88US=>	MYPTRW5ITVJ?
CAL-62	NHvKeJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHu2ZoNKSzVyPUCuNVYyPjlizszN	NVvTXG5TW0GQR1XS
HCC1937	NYTmVZIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17wcGlEPTB;MD6xOlI4PSEQvF2=	MnPoV2FPT0WU
NCI-H1299	NFXOWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\STWM2OD1yLkG2Nlg2KM7:TR?=	MXPTRW5ITVJ?
SW1088	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwMU[0NVMh\|ryP	M{L0UHNCVkeHUh?=
FTC-133	MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jJb2lEPTB;MD6xOlU1KM7:TR?=	MnzsV2FPT0WU
OC-314	M3XufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwMU[2PUDPxE1?	NV;GfVFEW0GQR1XS
SCC-9	NVO5WnRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLGVJVkUUN3ME2wMlE3PzF4IN88US=>	M13obHNCVkeHUh?=
HT-1376	NEDiUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfSfVlKSzVyPUCuNVY6OzZizszN	NVnr[3RXW0GQR1XS
U-2-OS	NGPuTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnftTWM2OD1yLkG3NVc{KM7:TR?=	MmHxV2FPT0WU
COLO-824	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMUeyPVQh\|ryP	NYjUbGIyW0GQR1XS
BB30-HNC	NFLRO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLWTWM2OD1yLkG3N\|Mh\|ryP	NYHoNYVQW0GQR1XS
NCI-H2087	NFXTRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\tbGlEPTB;MD6xO\|M3QCEQvF2=	MVTTRW5ITVJ?
NCI-H2170	NXvieWppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3adpBKSzVyPUCuNVc2OzZizszN	MmrsV2FPT0WU
SK-OV-3	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInsW\|FKSzVyPUCuNVc2PzFizszN	MorBV2FPT0WU
MZ7-mel	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonQTWM2OD1yLkG3OlQ6KM7:TR?=	NES5dWFUSU6JRWK=
NCI-H650	NFXoWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTvbXFKSzVyPUCuNVc3QDJizszN	NHWz[lhUSU6JRWK=
KOSC-2	NVzxTpV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnDOnNWUUN3ME2wMlE4PzN2IN88US=>	MlnrV2FPT0WU
SCC-4	M1L3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwMUe3O\|ch\|ryP	NH3iPYxUSU6JRWK=
MDA-MB-157	M3frPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vrTGlEPTB;MD6xPFA5OiEQvF2=	NV;BNHpUW0GQR1XS
KYSE-520	NIDhZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlu5TWM2OD1yLkG4NkDPxE1?	M2\mTXNCVkeHUh?=
LK-2	M4HQbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwMUizNFMh\|ryP	NGe1[G1USU6JRWK=
KNS-81-FD	M2Du[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\USHJKSzVyPUCuNVg{QTRizszN	MXXTRW5ITVJ?
IGROV-1	MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFr6VVdKSzVyPUCuNVg1PDNizszN	NGXJfo9USU6JRWK=
DEL	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2[0PWlEPTB;MD6xPFQ2KM7:TR?=	M2joUXNCVkeHUh?=
NCI-H1395	NGD1dYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFf2eIFKSzVyPUCuNVg3QDJizszN	MlToV2FPT0WU
JEG-3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3v5[GlEPTB;MD6xPFcxPSEQvF2=	NEnTfZRUSU6JRWK=
BCPAP	NVLJNHh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PiVmlEPTB;MD6xPFg4OiEQvF2=	NXHMW2Y{W0GQR1XS
CAL-27	MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwMUmwNlIh\|ryP	NVXEc4VDW0GQR1XS
RD	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\vTWM2OD1yLkG5NVE{KM7:TR?=	NWHhWJZoW0GQR1XS
RVH-421	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHy2PYFKSzVyPUCuNVkyOTZizszN	M3LTW3NCVkeHUh?=
Capan-2	M37GPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\tTWM2OD1yLkG5NlU3KM7:TR?=	MWfTRW5ITVJ?
COLO-680N	NVrZe2hoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDYNJZGUUN3ME2wMlE6OzZ2IN88US=>	NETMW2dUSU6JRWK=
NCI-H1650	NFn0XlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGO2fYhKSzVyPUCuNlAxPTdizszN	MYDTRW5ITVJ?
SBC-5	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPueHpKSzVyPUCuNlAyOThizszN	NEfqVIZUSU6JRWK=
U031	NVzyVVNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DtPWlEPTB;MD6yNFU1PyEQvF2=	MmLXV2FPT0WU
S-117	M3vjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmH6TWM2OD1yLkKwOVY1KM7:TR?=	NWm3WXBQW0GQR1XS
DoTc2-4510	M12w[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjTS4NKSzVyPUCuNlA4PjlizszN	NX\oV41zW0GQR1XS
AM-38	NXLyPJFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjLTWM2OD1yLkKwPFQ5KM7:TR?=	MkXQV2FPT0WU
A172	NIfKT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvSWm9KSzVyPUCuNlExOjJizszN	MofTV2FPT0WU
HPAF-II	NWTmV5lIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYX4WmlJUUN3ME2wMlIyOjZ2IN88US=>	M3Ox[nNCVkeHUh?=
769-P	MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTtVnJ2UUN3ME2wMlIyOjhizszN	MU\TRW5ITVJ?
MFE-280	NUS0SXg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwMkGyPVgh\|ryP	NEL6OHVUSU6JRWK=
TE-9	MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEe2WlZKSzVyPUCuNlE4QDZizszN	Mnq5V2FPT0WU
C2BBe1	MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETWU4dKSzVyPUCuNlIyQSEQvF2=	MlX0V2FPT0WU
EoL-1-cell	NHPjfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\WW5lKSzVyPUCuNlIzODNizszN	MUTTRW5ITVJ?
G-361	M3rlbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1X5U2lEPTB;MD6yNlY5OiEQvF2=	MorNV2FPT0WU
KYSE-270	MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljKTWM2OD1yLkKzNFg1KM7:TR?=	MVLTRW5ITVJ?
TK10	NHeySpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTue5QxUUN3ME2wMlI{OTF5IN88US=>	MmXZV2FPT0WU
ML-2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDuN3JmUUN3ME2wMlI{OTF7IN88US=>	Mmf3V2FPT0WU
MHH-ES-1	NVXaO3NnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwMkO2PFEh\|ryP	MWfTRW5ITVJ?
BHY	NUn2fJZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEL2[Y5KSzVyPUCuNlM3QTFizszN	NYf2ZYpnW0GQR1XS
LS-513	M{PofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTsU3RjUUN3ME2wMlI{QTZzIN88US=>	MXHTRW5ITVJ?
COLO-678	MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrWVnNKSzVyPUCuNlQxPDRizszN	NIDucIxUSU6JRWK=
NCI-H747	NH20WYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnS4TWM2OD1yLkK0NVY6KM7:TR?=	M17r[nNCVkeHUh?=
K5	M4nGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjT[phNUUN3ME2wMlI1OzhizszN	MX3TRW5ITVJ?
OS-RC-2	NGDoWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\FTms2UUN3ME2wMlI1PTB7IN88US=>	M1rlOHNCVkeHUh?=
KINGS-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTBwMkS1Nlkh\|ryP	NG\HVJFUSU6JRWK=
SCC-25	MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwMkS1OlMh\|ryP	MXnTRW5ITVJ?
CAPAN-1	NVrlVGx2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTmUmZuUUN3ME2wMlI1Pzh\|IN88US=>	MoKyV2FPT0WU
ESS-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHoTWM2OD1yLkK0PFA2KM7:TR?=	NHK2SGZUSU6JRWK=
TE-6	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMkW3OUDPxE1?	MWPTRW5ITVJ?
LB2518-MEL	M2TEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwMkW3O\|ch\|ryP	NUHIdJBxW0GQR1XS
COLO-800	M3TzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\McGZKSzVyPUCuNlU5OTJizszN	MXjTRW5ITVJ?
LU-134-A	NF25[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnT4TWM2OD1yLkK2NVM3KM7:TR?=	MVjTRW5ITVJ?
NCI-H1155	M2e3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPETWM2OD1yLkK2NVYzKM7:TR?=	NG\uTnVUSU6JRWK=
MFM-223	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnxRXB[UUN3ME2wMlI3OzZ\|IN88US=>	MmfjV2FPT0WU
HTC-C3	NHfWT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTSdm1KSzVyPUCuNlY2ODZizszN	NFXuNGRUSU6JRWK=
HCT-116	M4mxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrZZYtKSzVyPUCuNlY2QTlizszN	NGf3eVBUSU6JRWK=
Ca-Ski	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojiTWM2OD1yLkK2Olc5KM7:TR?=	MWnTRW5ITVJ?
SBC-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;4UGlEPTB;MD6yOlc1OiEQvF2=	M4fMZnNCVkeHUh?=
NB69	NXj2Vo97T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoCzTWM2OD1yLkK3NFg4KM7:TR?=	MnX0V2FPT0WU
J82	NEDnPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTBwMkeyOlUh\|ryP	NVnmcplmW0GQR1XS
U-118-MG	NF3td2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Hv[2lEPTB;MD6yO\|U4QSEQvF2=	NVvYOlJwW0GQR1XS
NCI-H1355	Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrZTWM2OD1yLkK4NFc1KM7:TR?=	NHLCU3BUSU6JRWK=
NCI-H1048	M1XPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUT3SpNPUUN3ME2wMlI5QTV4IN88US=>	NVn3T3l2W0GQR1XS
SW954	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\OTWM2OD1yLkK5NlI4KM7:TR?=	Mn;FV2FPT0WU
NMC-G1	NYG4RVFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHienlsUUN3ME2wMlI6Ojd5IN88US=>	NF[xe29USU6JRWK=
SW1710	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoW4TWM2OD1yLkK5OFk1KM7:TR?=	MnLrV2FPT0WU
KY821	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{K2NGlEPTB;MD6yPVg4OiEQvF2=	MlnQV2FPT0WU
HCC38	M1;MNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH:5eWdKSzVyPUCuN\|AxPzhizszN	NILwbFlUSU6JRWK=
NCI-SNU-5	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzKXY1KSzVyPUCuN\|A2PCEQvF2=	MkTEV2FPT0WU
ES8	NX:wemtGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzy[mxrUUN3ME2wMlMxPzh2IN88US=>	MlfTV2FPT0WU
COLO-792	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzGTWM2OD1yLkOxNlUyKM7:TR?=	NY\ScGVzW0GQR1XS
BFTC-905	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwM{G1NlEh\|ryP	NID0em1USU6JRWK=
ChaGo-K-1	NUPRO4ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjXTWM2OD1yLkOxO\|E2KM7:TR?=	NV3uRmNUW0GQR1XS
Daoy	NXO5V\|RvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPuWHdKSzVyPUCuN\|E4OjNizszN	NUK3OIpxW0GQR1XS
SJSA-1	NH;0fmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DNSWlEPTB;MD6zNVg1PyEQvF2=	Ml:1V2FPT0WU
KNS-62	MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnMfnhCUUN3ME2wMlMzODh6IN88US=>	MkSyV2FPT0WU
CAKI-1	NXPic\|ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTvUYZKSzVyPUCuN\|IyOTFizszN	M2X5ZnNCVkeHUh?=
UACC-62	MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXUOlZKSzVyPUCuN\|IzOjdizszN	NVPVO2VjW0GQR1XS
HuCCT1	M33lfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjESIZKSzVyPUCuN\|IzQDNizszN	M1TNUnNCVkeHUh?=
CTB-1	NEjTWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3[1[WlEPTB;MD6zNlc2OyEQvF2=	MoLEV2FPT0WU
NTERA-S-cl-D1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nBWmlEPTB;MD6zNlg{PiEQvF2=	MV;TRW5ITVJ?
T-24	NVXJc3RFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwM{OxOVkh\|ryP	M4TsdHNCVkeHUh?=
KYSE-70	MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwM{OyPFMh\|ryP	NWOwRoJzW0GQR1XS
SW626	Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LkfmlEPTB;MD6zN\|U{OiEQvF2=	NVzi[2U4W0GQR1XS
LB996-RCC	M3ToTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPnWVlOUUN3ME2wMlM{PjF7IN88US=>	MlzxV2FPT0WU
DMS-273	M1j5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwM{O5NVYh\|ryP	NF7TXJJUSU6JRWK=
SW1783	MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPDTWM2OD1yLkOzPVk4KM7:TR?=	M{TGPHNCVkeHUh?=
KU812	NWq2WGdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXwTWM2OD1yLkO0NFM5KM7:TR?=	MmLPV2FPT0WU
HSC-2	NUi5RpBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF72Xm5KSzVyPUCuN\|QxPTNizszN	NF3CXI9USU6JRWK=
A3-KAW	NUnQW\|FWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPuXY1KSzVyPUCuN\|QyPjJizszN	MV7TRW5ITVJ?
COLO-684	MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DxeWlEPTB;MD6zOFUxOSEQvF2=	MVXTRW5ITVJ?
NCI-H2405	MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvMOlVHUUN3ME2wMlM1PjNzIN88US=>	MnrDV2FPT0WU
NCI-H2228	M2rzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwM{WzOVch\|ryP	MWnTRW5ITVJ?
NB13	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;KSWlEPTB;MD6zOlgzQSEQvF2=	MV7TRW5ITVJ?
no-11	NGDh[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwM{[5OUDPxE1?	NECwOFRUSU6JRWK=
DK-MG	M2i2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;rSodTUUN3ME2wMlM4OTh6IN88US=>	NGrhbIdUSU6JRWK=
NBsusSR	NF21XlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnIZpZiUUN3ME2wMlM4Ojh3IN88US=>	MX7TRW5ITVJ?
KP-N-YS	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\v[WlEPTB;MD6zO\|Q3OyEQvF2=	M4C3UHNCVkeHUh?=
CFPAC-1	NG\6fFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HQeWlEPTB;MD6zO\|UyQCEQvF2=	NXLnT4xHW0GQR1XS
KARPAS-45	Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fDemlEPTB;MD6zO\|g3OiEQvF2=	NHH6RmxUSU6JRWK=
NCI-H1793	NUfhZZNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLvTWM2OD1yLkO4OVEh\|ryP	Ml3KV2FPT0WU
HCE-T	M{PWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGP2NJpKSzVyPUCuN\|g3ODNizszN	MorPV2FPT0WU
NCI-H520	NWOwVJZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVSwd5pVUUN3ME2wMlM5PzB\|IN88US=>	M333XXNCVkeHUh?=
HCC2157	M3XDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwM{i3PFEh\|ryP	NHXob3hUSU6JRWK=
EW-18	MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1i3dmlEPTB;MD6zPFk1OSEQvF2=	NIXwfHNUSU6JRWK=
RO82-W-1	NYfnVopmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1:yZ2lEPTB;MD6zPVY6QSEQvF2=	M4XqVHNCVkeHUh?=
HuP-T3	NXjWUJdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX64OZpXUUN3ME2wMlQxOTR\|IN88US=>	M{\mRnNCVkeHUh?=
PANC-10-05	M1HxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULaV\|k{UUN3ME2wMlQyOTdizszN	M{PyWXNCVkeHUh?=
NCI-H1703	NFGxd\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfQVZFKSzVyPUCuOFE1PDZizszN	NVjvZZViW0GQR1XS
TE-10	NWqxUFdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvqTWM2OD1yLkSxOFQ4KM7:TR?=	M3XKUHNCVkeHUh?=
HOS	NFTqcmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mme1TWM2OD1yLkSxOlgzKM7:TR?=	M2DEbXNCVkeHUh?=
LN-405	MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPvTWM2OD1yLkSxOlg4KM7:TR?=	NV60ZZZ7W0GQR1XS
A427	M2HvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4C2XmlEPTB;MD60NVk5OSEQvF2=	MXnTRW5ITVJ?
CAL-12T	NYrWPJY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojHTWM2OD1yLkSyO\|gh\|ryP	MkWwV2FPT0WU
SW756	NWLSeIRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfnTWM2OD1yLkS0NVg{KM7:TR?=	M4W5cHNCVkeHUh?=
YAPC	NXW2PWRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{GzdGlEPTB;MD60OVA5KM7:TR?=	NYi5enFGW0GQR1XS
GOTO	NVq2NGNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTBwNEWxOkDPxE1?	NEfvXVZUSU6JRWK=
C3A	M3nUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorhTWM2OD1yLkS1OFM4KM7:TR?=	NWTDXGg4W0GQR1XS
UM-UC-3	Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTBwNEW0O{DPxE1?	NUfHPWJuW0GQR1XS
NCI-H1573	M{jnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4OzU2lEPTB;MD60OVU3QSEQvF2=	M13MTXNCVkeHUh?=
LS-411N	NUnSUFVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrmTWM2OD1yLkS2OVI4KM7:TR?=	MmLLV2FPT0WU
COR-L23	M1;kWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XYRWlEPTB;MD60Olc3PCEQvF2=	MnX3V2FPT0WU
HCE-4	M{TY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPlNJNEUUN3ME2wMlQ4PDR4IN88US=>	MVvTRW5ITVJ?
NCI-H2291	MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwNEe4PVYh\|ryP	Mnz5V2FPT0WU
A101D	NYPqXFdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2Doe2lEPTB;MD60PFA2OyEQvF2=	MkfJV2FPT0WU
HT-3	MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\vUGZEUUN3ME2wMlQ5OjF5IN88US=>	NYi1U5J7W0GQR1XS
HOP-62	M3LlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGe5NYVKSzVyPUCuOFk5PjVizszN	NGjMbmFUSU6JRWK=
PC-3	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwNUG1NFch\|ryP	NWe5UWpUW0GQR1XS
CTV-1	NFW5[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwNUK2Olkh\|ryP	NXHtc2ZDW0GQR1XS
PANC-08-13	NYnTXIl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonXTWM2OD1yLkWzNVc4KM7:TR?=	NGfZOYdUSU6JRWK=
CAL-120	NX7TbmpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LKNmlEPTB;MD61N\|M6QSEQvF2=	NUnDPZpxW0GQR1XS
UMC-11	NFW5fIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTBwNUWyN\|Qh\|ryP	NV\ySXFzW0GQR1XS
MSTO-211H	M2i3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfj[XdKSzVyPUCuOVU4PjJizszN	MV7TRW5ITVJ?
NCI-H2126	M4XPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwNU[4NVUh\|ryP	NE\qdY9USU6JRWK=
SNU-C2B	NIL6dpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmG5TWM2OD1yLkW3PVc4KM7:TR?=	M3rsTnNCVkeHUh?=
DBTRG-05MG	NIfmXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnT6TWM2OD1yLkW4NFU{KM7:TR?=	NXnLbYFTW0GQR1XS
MKN1	NGXqR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPGRYtKSzVyPUCuOVg4QDNizszN	NWXCSHhCW0GQR1XS
ES3	M{D5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TQSWlEPTB;MD61PVEzPCEQvF2=	MXfTRW5ITVJ?
OVCAR-3	Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmThTWM2OD1yLkW5N\|QyKM7:TR?=	MV7TRW5ITVJ?
ACHN	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwNkC1Olkh\|ryP	MUDTRW5ITVJ?
SW872	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnS3TWM2OD1yLk[wO\|Y{KM7:TR?=	MYHTRW5ITVJ?
CP66-MEL	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MontTWM2OD1yLk[wPVY6KM7:TR?=	NV62bIRiW0GQR1XS
NCI-H661	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3KTWM2OD1yLk[xNVA1KM7:TR?=	NIWyOGxUSU6JRWK=
UACC-893	MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfxS4pKSzVyPUCuOlM3QDFizszN	NIK4WGZUSU6JRWK=
JVM-3	NHvGcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHUc5FIUUN3ME2wMlY{QDB2IN88US=>	MonkV2FPT0WU
SF268	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwNkSzOFkh\|ryP	M3:0NnNCVkeHUh?=
OCI-AML2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljWTWM2OD1yLk[1N\|k4KM7:TR?=	MljrV2FPT0WU
RPMI-8226	MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwNk[zNlMh\|ryP	NV2xdWdQW0GQR1XS
MKN28	MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXrTGRKSzVyPUCuOlY3OjRizszN	NUfOPVdSW0GQR1XS
MDA-MB-453	NVPJfoNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnL0TWM2OD1yLk[3NVgh\|ryP	NYfwOYtWW0GQR1XS
BV-173	MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\JTWM2OD1yLk[4Olc6KM7:TR?=	MkPGV2FPT0WU
NCI-H358	M2nabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYi3TItpUUN3ME2wMlY5PzJ4IN88US=>	MYHTRW5ITVJ?
NCI-H1651	NYewS2tDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEe2XHdKSzVyPUCuO{DPxE1?	NELQ[ZBUSU6JRWK=
MDA-MB-415	NIDtSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXQTWM2OD1yLkewPFI6KM7:TR?=	NF;a[3NUSU6JRWK=
8305C	Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGq5bG9KSzVyPUCuO\|I1QThizszN	M17Vd3NCVkeHUh?=
EFM-19	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY[3VVViUUN3ME2wMlc{PjdzIN88US=>	NGjlb2dUSU6JRWK=
RERF-LC-MS	NEnMfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwN{S2NVMh\|ryP	MVTTRW5ITVJ?
A388	MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLHUYRKSzVyPUCuO\|Y1PjdizszN	MmK1V2FPT0WU
GI-ME-N	NGjhO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\BTWM2OD1yLke3NlM2KM7:TR?=	NFTaS3FUSU6JRWK=
IGR-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LNOWlEPTB;MD63PVA1OyEQvF2=	NGrRXlZUSU6JRWK=
LNCaP-Clone-FGC	MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmD0TWM2OD1yLkiwNFA1KM7:TR?=	M1zERXNCVkeHUh?=
SK-MEL-3	NXe2XIoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTBwOEG1NFgh\|ryP	NIDZWo9USU6JRWK=
UACC-257	Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwOEKyN\|Eh\|ryP	M1fwcnNCVkeHUh?=
OE33	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTIdXpEUUN3ME2wMlg2OTBzIN88US=>	M4Lqb3NCVkeHUh?=
QIMR-WIL	NH6wT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LXemlEPTB;MD64OVE1OSEQvF2=	NFyyTotUSU6JRWK=
NCI-H2009	MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwOEWzNVEh\|ryP	NV\tbHVIW0GQR1XS
NCI-H522	NIHhNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwOEe3PFMh\|ryP	MnHiV2FPT0WU
Saos-2	M{fMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLQTWM2OD1yLki3PFcyKM7:TR?=	NEC5[5NUSU6JRWK=
NB17	MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXRTWM2OD1yLki4NFI2KM7:TR?=	MYfTRW5ITVJ?
D-392MG	NFew[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwOEmzOVYh\|ryP	M1PwTnNCVkeHUh?=
SHP-77	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1i1W2lEPTB;MD65NFQ5PSEQvF2=	M2rkOHNCVkeHUh?=
SK-MEL-30	MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwOUGxPFUh\|ryP	MVzTRW5ITVJ?
GCIY	Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DremlEPTB;MD65NVg1OyEQvF2=	NGXOTo9USU6JRWK=
HCC70	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHf2dlZKSzVyPUCuPVIxPTlizszN	MWrTRW5ITVJ?
LU-65	M4fDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHwTmRDUUN3ME2wMlkzPTlzIN88US=>	NFm4bHNUSU6JRWK=
NCI-H1563	NVHQbWl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XGeWlEPTB;MD65OFg3PSEQvF2=	MWrTRW5ITVJ?
KURAMOCHI	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVSydWFlUUN3ME2wMlk2OTl{IN88US=>	NWrCeHh[W0GQR1XS
PA-1	Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjQZYM6UUN3ME2wMlk2PDJ2IN88US=>	NULT[o1MW0GQR1XS
NOS-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjQ[ZhxUUN3ME2wMlk4PDh7IN88US=>	M4fYdHNCVkeHUh?=
NCI-H69	NFfReHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LFbWlEPTB;MD65O\|Y{PCEQvF2=	MlTFV2FPT0WU
KYSE-450	NV;GWZBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLmXGlHUUN3ME2wMlk5PjJ4IN88US=>	NVq1OWw5W0GQR1XS
8505C	NFfoc5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwOUm5PFIh\|ryP	MVzTRW5ITVJ?
TGBC24TKB	NH3tcHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnRU\|ZsUUN3ME2xMlAxODh2IN88US=>	M4f2bnNCVkeHUh?=
PFSK-1	NU\RNI9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTFwMEG0Nlgh\|ryP	NHy2XHRUSU6JRWK=
EKVX	NWGzfWU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWGxPHEzUUN3ME2xMlA{OTJzIN88US=>	NXXm[mZWW0GQR1XS
RCM-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrqcWdPUUN3ME2xMlA2PTB5IN88US=>	MXnTRW5ITVJ?
SW900	NET2UXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTFwMEe4N{DPxE1?	MlTDV2FPT0WU
D-542MG	M3H4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTkW2w4UUN3ME2xMlA4QDV3IN88US=>	M3X3UXNCVkeHUh?=
SK-PN-DW	M3;YW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTFwMUCwOVYh\|ryP	NEXIVWVUSU6JRWK=
NCI-H727	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTFwMUCxOVQh\|ryP	NE\VVXRUSU6JRWK=
SW837	M2rEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2OyWWlEPTB;MT6xNFk2PCEQvF2=	Ml;PV2FPT0WU
BT-20	M1jHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHT3SYNKSzVyPUGuNVEzODRizszN	MoDhV2FPT0WU
RH-18	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjFb\|BKSzVyPUGuNVMyODNizszN	MorhV2FPT0WU
TE-12	MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTFwMUOzN\|Mh\|ryP	MmTaV2FPT0WU
NB10	NEXSNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DMZ2lEPTB;MT6xN\|M1PCEQvF2=	NHr0[\|FUSU6JRWK=
AU565	M{\HT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3tTWM2OD1zLkG1PVc{KM7:TR?=	MXzTRW5ITVJ?
OAW-42	MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTpeodyUUN3ME2xMlE5OzB4IN88US=>	MmLXV2FPT0WU
DJM-1	MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3hTWM2OD1zLkG5PFgyKM7:TR?=	NWOzN292W0GQR1XS
HH	NI\q[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fGOGlEPTB;MT6yN\|g{OSEQvF2=	NVnvXY1zW0GQR1XS
LAMA-84	NYr5TnduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI[0UZdKSzVyPUGuNlc{QTRizszN	M2jZd3NCVkeHUh?=
KNS-42	NVHJOIpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mon2TWM2OD1zLkOwNlk3KM7:TR?=	MWDTRW5ITVJ?
NCI-H2052	NV70TmkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFL1bGlKSzVyPUGuN\|A2ODdizszN	NWjhPHdYW0GQR1XS
MLMA	NF7xe2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTFwM{K0NFch\|ryP	NUnxU5ZiW0GQR1XS
NB12	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXP[mRKSzVyPUGuN\|U3OzZizszN	M4i2S3NCVkeHUh?=
NCI-H1838	Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTFwM{[zNFYh\|ryP	NFTtW5pUSU6JRWK=
NCI-H526	MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HndWlEPTB;MT6zO\|g2OyEQvF2=	MWTTRW5ITVJ?
LS-123	NEDse3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjhNJBKSzVyPUGuN\|kxQTRizszN	M1zUPHNCVkeHUh?=
HDLM-2	MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nTfWlEPTB;MT6zPVI4OSEQvF2=	M{\CPXNCVkeHUh?=
MC-IXC	NVzUR3NOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFewTndKSzVyPUGuOFI{PzFizszN	NHvNco1USU6JRWK=
HCT-15	MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTFwNEOwOlgh\|ryP	NHLFNplUSU6JRWK=
NCI-H596	MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX30XI04UUN3ME2xMlQ2ODZzIN88US=>	NFLmR25USU6JRWK=
ZR-75-30	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTFwNEewPFIh\|ryP	NWHBWHF4W0GQR1XS
A704	M4rVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjqVY9KSzVyPUGuOlY2PjNizszN	NF;m[YRUSU6JRWK=
OVCAR-4	NFfz[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlKzTWM2OD1zLk[5OlA4KM7:TR?=	NILuWXBUSU6JRWK=
SW1417	NGDpS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTFwN{K4OFkh\|ryP	NWTnPIdjW0GQR1XS
CAS-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2qycmlEPTB;MT63N\|k{PiEQvF2=	MlzpV2FPT0WU
IST-SL1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DSPWlEPTB;MT63PVc2QSEQvF2=	MoDaV2FPT0WU
A253	M2q3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfvN5h3UUN3ME2xMlgzOjN7IN88US=>	MnvWV2FPT0WU
EW-16	NUfzS3ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUj4PG1nUUN3ME2xMlgzQDd3IN88US=>	NHm1[2tUSU6JRWK=
SK-NEP-1	NUTnT4RnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkC1TWM2OD1zLki2PVg5KM7:TR?=	MmLrV2FPT0WU
NCI-H226	NXzzW4hoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTFwOEmzOVkh\|ryP	Mmn3V2FPT0WU
HOP-92	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nKfGlEPTB;MT65OlA6QSEQvF2=	NGK0XXBUSU6JRWK=
NCI-H441	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTJwMEKzN\|ch\|ryP	NWnZXpNNW0GQR1XS
LU-139	Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTJwMEOxNVQh\|ryP	MmSzV2FPT0WU
SJRH30	NWD4V29IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUH3SpFrUUN3ME2yMlA1OjV\|IN88US=>	NFjMfWZUSU6JRWK=
MG-63	NVjLPWZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPXRlBKSzVyPUKuNVQyOTFizszN	M3zTe3NCVkeHUh?=
NH-12	M3OzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jScGlEPTB;Mj6xOVAxPiEQvF2=	NFvXZmxUSU6JRWK=
NB7	M1jPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4D6N2lEPTB;Mj6xPVY4OyEQvF2=	M13qfnNCVkeHUh?=
LB771-HNC	NE[xeHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\QTG9KSzVyPUKuNlA2QTVizszN	MoDGV2FPT0WU
HCC1569	MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk[5TWM2OD1{LkK0OVg{KM7:TR?=	MXnTRW5ITVJ?
D-283MED	MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLXTWM2OD1{LkK0O\|gzKM7:TR?=	M3f5OHNCVkeHUh?=
J-RT3-T3-5	NV3aSmZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7re4ZKSzVyPUKuNlU{PTFizszN	NXrCNJY{W0GQR1XS
ATN-1	M2G0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfPenlKSzVyPUKuN\|MxQDJizszN	NFXoOpZUSU6JRWK=
HCC1954	Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nZS2lEPTB;Mj6zOFQxQCEQvF2=	NXP2eIo3W0GQR1XS
SCC-15	NETJZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTJwM{mzNVIh\|ryP	MVvTRW5ITVJ?
COLO-668	M2nNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHUTWM2OD1{LkSzNkDPxE1?	NIDWTG1USU6JRWK=
LB373-MEL-D	MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLoPVV7UUN3ME2yMlU1Pjd5IN88US=>	NGDnOmJUSU6JRWK=
no-10	Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlP2TWM2OD1{LkW0PVQ4KM7:TR?=	MUjTRW5ITVJ?
HT-1197	M1TSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTJwNkOxPFgh\|ryP	NE\FeZZUSU6JRWK=
DU-145	NHGwZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfZ[WFKSzVyPUKuO\|kyPjJizszN	MnLzV2FPT0WU
SK-N-AS	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjOdZNpUUN3ME2yMlg1Pjl{IN88US=>	M4PXTnNCVkeHUh?=
MOLT-4	NEjDemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFf2SJZKSzVyPUKuPFU{OjJizszN	MnvSV2FPT0WU
EW-22	M2r2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTJwOUK4OFEh\|ryP	MmLUV2FPT0WU
DB	NVG0eYN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3uTWM2OD1{Lkm3O\|U6KM7:TR?=	MlrGV2FPT0WU
HL-60	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\YXXJyUUN3ME2zMlA1Ozd4IN88US=>	NGDuWVVUSU6JRWK=
SK-N-DZ	NXXSe3Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTUSWRKSzVyPUOuNFUxPzVizszN	NGLD[2pUSU6JRWK=
NY	MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zsUmlEPTB;Mz6wPFU1OiEQvF2=	NFPve4FUSU6JRWK=
T47D	MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{ntNWlEPTB;Mz6xNFU2QCEQvF2=	M3\kbnNCVkeHUh?=
NCI-H2029	Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NET4dGNKSzVyPUOuNlI1PzdizszN	Mlz4V2FPT0WU
KARPAS-299	NHnoeJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mki5TWM2OD1\|LkK2NFI4KM7:TR?=	MVTTRW5ITVJ?
KM-H2	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn:1TWM2OD1\|LkOwOlgh\|ryP	NGPuRVFUSU6JRWK=
CHP-134	NFjGcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTNwNEezPUDPxE1?	MV\TRW5ITVJ?
22RV1	MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1n5O2lEPTB;Mz60PVE3QCEQvF2=	Mkj3V2FPT0WU
NB5	NIfUWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vyVGlEPTB;Mz61NFY5QSEQvF2=	M4DCPXNCVkeHUh?=
CW-2	NWPtVZlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrPTJdKSzVyPUOuOVU{OTRizszN	MoXEV2FPT0WU
EFO-21	M{nmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvtTWM2OD1\|LkW2PVQh\|ryP	MnrnV2FPT0WU
HuH-7	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnGyTWM2OD1\|LkW4OFE1KM7:TR?=	NF;LRW9USU6JRWK=
ALL-PO	NEO0NXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDDTWM2OD1\|Lk[yN\|M2KM7:TR?=	MkXqV2FPT0WU
EM-2	M17J[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nlbGlEPTB;Mz62PVAyOSEQvF2=	Mk[0V2FPT0WU
KLE	MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTNwN{OwNlkh\|ryP	MnW1V2FPT0WU
NEC8	NV\j[ZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTNwOUG4NFgh\|ryP	M1vBcHNCVkeHUh?=
KP-N-YN	NVSy[HBGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTNwOUO0O\|Yh\|ryP	NGXHU\|FUSU6JRWK=
SK-MEL-1	M1G4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vLPGlEPTB;ND6wN\|UyQCEQvF2=	Mn;4V2FPT0WU
CAL-54	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGraSplKSzVyPUSuNFU6OSEQvF2=	MUHTRW5ITVJ?
MS-1	M{KxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M136WmlEPTB;ND6xOlE2PSEQvF2=	MmDYV2FPT0WU
NCI-H209	M1jKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjt[oNKSzVyPUSuNlk6QTlizszN	NXjlUGZ{W0GQR1XS
NOMO-1	NWfZ[VVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2Oye2lEPTB;ND6zNlE{OSEQvF2=	M33ybnNCVkeHUh?=
RPMI-2650	NV34UHlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPwTWM2OD12LkO2N\|I4KM7:TR?=	NWnOblJQW0GQR1XS
NCI-H810	NFXGSZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\tU\|JsUUN3ME20MlM6PzN4IN88US=>	M2PWRnNCVkeHUh?=
Ca9-22	Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrDTWM2OD12LkS1OlkyKM7:TR?=	Mn7PV2FPT0WU
ES4	Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHj5TmZKSzVyPUSuOFcxQTVizszN	MXnTRW5ITVJ?
ES6	NELtXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTRwNEm2OVch\|ryP	M2Hk[HNCVkeHUh?=
DMS-114	M4n5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LqPGlEPTB;ND61OFY6OSEQvF2=	MVnTRW5ITVJ?
ONS-76	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXifGdOUUN3ME20MlU4QTVizszN	MXPTRW5ITVJ?
K-562	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXFN2VqUUN3ME20Mlc{QDF2IN88US=>	MYfTRW5ITVJ?
MHH-NB-11	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTRwN{W0OlEh\|ryP	MUnTRW5ITVJ?
Calu-3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3G5ZWlEPTB;ND63PFU1QCEQvF2=	MXrTRW5ITVJ?
HT55	NVvKO2NbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDsTWM2OD12Lki0OVQ2KM7:TR?=	MVfTRW5ITVJ?
SK-N-FI	MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;aTWM2OD12Lki1NFA6KM7:TR?=	NVfQ[2dMW0GQR1XS
ES1	NXjLeWU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTRwOE[wOVch\|ryP	Ml3TV2FPT0WU
SF126	NFyySHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTRwOUOxPFQh\|ryP	MoLTV2FPT0WU
ES5	MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3YTWM2OD13LkGyOFI4KM7:TR?=	NV\IU\|k5W0GQR1XS
LoVo	NHP2eZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTVwMUW4O\|Eh\|ryP	M1HPXHNCVkeHUh?=
SNU-387	M1\hNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTH[3B7UUN3ME21MlMzOzN7IN88US=>	MVPTRW5ITVJ?
C8166	NVP2d3VqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTVwM{[zN\|kh\|ryP	NH[4SItUSU6JRWK=
LS-1034	NILSOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjJfWlKSzVyPUWuOFI{ODdizszN	MU\TRW5ITVJ?
GR-ST	NY\DclJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnKboc{UUN3ME21MlUzOjBzIN88US=>	NYHINllyW0GQR1XS
NCI-H1092	MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTVwN{K4OFMh\|ryP	NGPkWYNUSU6JRWK=
647-V	NVHKWmV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PxSmlEPTB;NT63OFcxPiEQvF2=	M2PwXnNCVkeHUh?=
EW-13	NELtUVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnGPW9KSzVyPUWuO\|Y3OjdizszN	MnLjV2FPT0WU
KGN	MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTZwMEm5NlEh\|ryP	MnTHV2FPT0WU
D-423MG	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTZwNECyPFQh\|ryP	M33HZXNCVkeHUh?=
ECC10	NHHGdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTdwMUCxNFEh\|ryP	MmLqV2FPT0WU
TE-5	M3Tpbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTdwNEGyPVgh\|ryP	M3HLVXNCVkeHUh?=
P12-ICHIKAWA	NVLqdWtxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTdwNEW1NlMh\|ryP	Mn3lV2FPT0WU
NCI-H82	NX32OIxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTdwNEW3NFEh\|ryP	M1nLVnNCVkeHUh?=
NCI-H1993	MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnZRVg5UUN3ME23Mlg{ODZ\|IN88US=>	M{\3N3NCVkeHUh?=
RH-1	NELSU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorOTWM2OD15Lki1NlQ1KM7:TR?=	MYTTRW5ITVJ?
SW948	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzifmRMUUN3ME23Mlk3ODR7IN88US=>	M1\SSHNCVkeHUh?=
CAL-33	NGjEWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDnbYNOUUN3ME23Mlk6QTN6IN88US=>	NFn0TplUSU6JRWK=
U-266	MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTrSXY2UUN3ME24MlE2Pzd5IN88US=>	NF3a[\|RUSU6JRWK=
CAL-72	M3LYVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4S5ZmlEPTB;OD6yNFMzKM7:TR?=	MXTTRW5ITVJ?
SNU-423	NEPhT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nXPGlEPTB;OT6zOlY3PiEQvF2=	NXXLTGY4W0GQR1XS
KG-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\PXpgxUUN3ME25MlU5PDV4IN88US=>	NWK2VmZtW0GQR1XS
HCC1395	MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PiXGlEPTB;OT65NlM2OiEQvF2=	NXHURY5ZW0GQR1XS
BE-13	M2XFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTFyLki4PVIh\|ryP	MmP6V2FPT0WU
MKN7	MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTFyLkm3OlUh\|ryP	M33hT3NCVkeHUh?=
697	NYDPRW9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGH6W25KSzVyPUGxMlE1PzJizszN	MX3TRW5ITVJ?
LU-135	NVLVN\|FuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTFzLkKzNFch\|ryP	NHv6eWtUSU6JRWK=
ES7	NYrES2p6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTFzLkOzNVMh\|ryP	MV7TRW5ITVJ?
SK-HEP-1	MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LvPGlEPTB;MUGuO\|Y1PiEQvF2=	MX;TRW5ITVJ?
BEN	M2nUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmeyTWM2OD1zMT64OVEh\|ryP	M4r4S3NCVkeHUh?=
NCI-H1770	Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2C3PWlEPTB;MUKuNVI3KM7:TR?=	M3TXV3NCVkeHUh?=
SW13	NInXcmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLEdI1KSzVyPUGyMlE2PDFizszN	NVL0XY5tW0GQR1XS
MZ1-PC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\MTWM2OD1zMj61OFUzKM7:TR?=	NEn0emNUSU6JRWK=
Mo-T	NFr1ZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\ZS2lEPTB;MUKuO\|QzOSEQvF2=	Mli2V2FPT0WU
HLE	NYjpeJB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmP3TWM2OD1zMj64NlE2KM7:TR?=	NWr4SodYW0GQR1XS
RCC10RGB	MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXCTWM2OD1zMz62O\|Eh\|ryP	NFj6bI1USU6JRWK=
COLO-320-HSR	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjnb3BKSzVyPUGzMlc{QDFizszN	NFHUcJVUSU6JRWK=
BHT-101	M3r5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\rSGlEPTB;MUOuPFM1PSEQvF2=	MU\TRW5ITVJ?
OCUB-M	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4W0NmlEPTB;MUSuNVYxOiEQvF2=	NFfI[lhUSU6JRWK=
MEG-01	MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TLTGlEPTB;MUSuN\|cxQCEQvF2=	MojwV2FPT0WU
RS4-11	M1ix[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTF2Lke0NkDPxE1?	NYjBWVd7W0GQR1XS
MN-60	NHjPWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTF2Lke4PVQh\|ryP	NUXLZ4duW0GQR1XS
NCI-H1304	NIDmeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjyeXB1UUN3ME2xOU4xPDJ3IN88US=>	NEXjfVlUSU6JRWK=
Ramos-2G6-4C10	NFjQdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33HNGlEPTB;MUWuNFU5OSEQvF2=	Mn\LV2FPT0WU
NCI-H2342	NGD4[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIP5VoFKSzVyPUG1MlIxPDRizszN	MnTsV2FPT0WU
LAN-6	MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDn[ZJDUUN3ME2xOU41PDF2IN88US=>	M4nCenNCVkeHUh?=
JVM-2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULwZohlUUN3ME2xOU42PzR6IN88US=>	MXTTRW5ITVJ?
P30-OHK	NHrR[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTMbVJ4UUN3ME2xOk4xPjF2IN88US=>	NIO0OGtUSU6JRWK=
C-33-A	MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTF4Lk[yNVQh\|ryP	NFGzcVNUSU6JRWK=
RPMI-8866	NXX3OotFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfjTWM2OD1zNj64OFk3KM7:TR?=	MV7TRW5ITVJ?
NCI-H630	NGXrclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjFTWM2OD1zNj64OVM4KM7:TR?=	MVrTRW5ITVJ?
KYSE-140	NE\C[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\qTWM2OD1zNz6yNFI5KM7:TR?=	NXHhUm9KW0GQR1XS
T84	MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzNOpBKSzVyPUG4Mlg3QTVizszN	MWrTRW5ITVJ?
KU-19-19	Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPyTWM2OD1zOD65OlA5KM7:TR?=	M3iy[3NCVkeHUh?=
BALL-1	NETNWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\VTWM2OD1zOT6zN\|k6KM7:TR?=	MX\TRW5ITVJ?
Calu-6	NVHF[JQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLBZoNKSzVyPUG5MlQ6OiEQvF2=	M4W1T3NCVkeHUh?=
EGI-1	M2HIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfTXndKSzVyPUG5MlU6QCEQvF2=	MV3TRW5ITVJ?
MFH-ino	NX\zS5NLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PrN2lEPTB;MUmuO\|Q2PCEQvF2=	M2rTXnNCVkeHUh?=
GB-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3S3bmlEPTB;MkCuN\|U{PSEQvF2=	M{LzfnNCVkeHUh?=
NCI-H1693	NYLhbWJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7PWm5wUUN3ME2yNE43PTB3IN88US=>	M{WwUnNCVkeHUh?=
SW1116	NF\5UY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDi[XNKSzVyPUKwMlk{PjJizszN	MXLTRW5ITVJ?
H-EMC-SS	NFPBPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTJ{LkC0OUDPxE1?	NVrzRXV7W0GQR1XS
D-502MG	NEDodIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXveIR2UUN3ME2yNk45OjZzIN88US=>	MXHTRW5ITVJ?
IA-LM	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXL6PIc2UUN3ME2yN{4zPDl\|IN88US=>	NF;mXIpUSU6JRWK=
SW1463	M3rLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTJ\|Lke5JO69VQ>?	NHG2V2dUSU6JRWK=
JAR	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULoWWNKUUN3ME2yOE4{Ojl\|IN88US=>	M17ONnNCVkeHUh?=
HT	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXvd29KSzVyPUK0MlQ4PTNizszN	M1L6bnNCVkeHUh?=
LCLC-103H	M1TvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnn1TWM2OD1{ND64OFQ6KM7:TR?=	MUHTRW5ITVJ?
SNU-449	NEDPPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTJ2Lki3OFEh\|ryP	MXPTRW5ITVJ?
KE-37	NF\yTIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\jTWM2OD1{NT6wPVI5KM7:TR?=	NWHofVJCW0GQR1XS
NCI-H1623	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHvTItKSzVyPUK3MlE{ODNizszN	M3jrSnNCVkeHUh?=
MOLT-13	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnNTWM2OD1{Nz6zOVE3KM7:TR?=	NGTHPIdUSU6JRWK=
COLO-741	NWTQcmlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDDNXBUUUN3ME2zNU4{OzN\|IN88US=>	NXvC[FdPW0GQR1XS
NB6	MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTN{LkK4O\|Yh\|ryP	NFzZbYlUSU6JRWK=
MOLT-16	M2f6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHQTWM2OD1\|Mz6wNFU2KM7:TR?=	MX\TRW5ITVJ?
IST-MES1	NF23TnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTN2LkC1OFEh\|ryP	M2LwV3NCVkeHUh?=
A4-Fuk	NHvhUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Thb2lEPTB;M{WuNFY3KM7:TR?=	Mmq2V2FPT0WU
CAL-85-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV:yeGhrUUN3ME2zOU4zQDF5IN88US=>	NVTKRYxKW0GQR1XS
CCRF-CEM	MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXvW4NRUUN3ME2zO{4yPTN4IN88US=>	MnK5V2FPT0WU
HAL-01	NX\0Nlg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrTcnJKSzVyPUO4MlQ5QDlizszN	NFficYhUSU6JRWK=
HEL	M3jTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XFfmlEPTB;NEOuN\|QxQSEQvF2=	MnW1V2FPT0WU
EW-1	M13ZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTR\|LkS3Olgh\|ryP	MX3TRW5ITVJ?
MDA-MB-231	M{jiW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIK2UJFKSzVyPUS1MlEyQTlizszN	MkHsV2FPT0WU
ABC-1	NUS5RmJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTR4Lki1N\|gh\|ryP	NV\zO41[W0GQR1XS
NCI-H446	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIT3[4xKSzVyPUS4MlUxPThizszN	NHX5emxUSU6JRWK=
MHH-PREB-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTIdotKSzVyPUS5MlYxODdizszN	MljlV2FPT0WU
DOHH-2	MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTR7Lk[2OVYh\|ryP	MkSwV2FPT0WU
GCT	NXPGVZRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1Swd2lEPTB;NEmuOlk4PiEQvF2=	NIXjRXFUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	α-Synuclein / HSP90 / HSP70 / HSP32 / αB-Crystallin; PubMed: 20090920 PLoS One Immunoblot analysis of heat shock protein induction. Cells were treated with 17-AAG (1–200 nM, 24 h), or subjected to heat shock (HS: 44°C, 30 min, 24 h recovery) or to MG-132 (MG: 1 µM, 24 h). Cell lysates were prepared and immunoblot analysis was carried out with antibodies against the individual proteins as indicated on the right. Co, untreated control. EGFR / PDGFR / AKT / MAPK / c-RAS; PubMed: 18682579 Neuro Oncol 17-AAG promotes the degradation of HSP90 client proteins that are involved in the pathology of glioblastoma multiforme (GBM). Glioma cell lines were treated with increasing concentrations of 17-AAG for 48 h, and protein lysates were run on Western blots. HSP90 client proteins known to be involved in gliomagenesis showed degradation while nonclient proteins remained unaffected by 17-AAG treatment. pAKT / pMAPK / pRb; PubMed: 18682579 Neuro Oncol The phosphorylated states of signaling proteins involved in glioma growth are also affected by 17-AAG treatment. Cleaved PARP / Survivin; PubMed: 18827603 J Thorac Oncol Western analysis of expression levels of cleaved PARP and Survivin in MM cell lines. β-Actin served as loading control. LATS1 / p-LATS1 / YAP / CTGF; PubMed: 25712415 J Cell Mol Med Effects of 17-AAG on the expression of LATS1, p-LATS1, YAP and CTGF. The expression levels of YAP and CTGF proteins, indicated by Western blot assay, were down-regulated, while LATS1 was upregulated in a dose-dependent manner in 17-AAG treated groups compared to the untreated group.	20090920 18682579 18827603 25712415
Immunofluorescence	STAT3; PubMed: 27279418 Mol Med Rep Effects of 17-AAG on STAT3 expression of H446 cells. (A) Control group; (B) 3.125 mg/l; (C) 6.25 mg/l. 17-AAG, 17-allylamino-17-demethoxygel-danamycin; STAT3, signal transducer and activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole. YAP / TAZ; PubMed: 25290150 PLoS One Reduction in cytoplasmic distribution accompanied by increased nuclear localization of YAP/TAZ was more apparent in cells treated with 45 nM 17-AAG (red channel for YAP/TAZ and blue channel for nucleus). Statistical comparisons were performed using one-way Kruskal-Wallis multiple comparison, ***p<0.001 compared with control (0 nM). β-catenin / E-cadherin; PubMed: 25290150 PLoS One Co-localization of β-catenin (Red) and E-cadherin (Green) was observed at the cell-cell junctions (white arrows) both in siCtrl and siCTGF cells after 17-AAG treatment. Scale bar is 20 µm.	27279418 25290150
Growth inhibition assay	Cell viability; PubMed: 18682579 Neuro Oncol 17-AAG inhibits the growth of human glioma cell lines. Human glioma cell lines and a nontumorigenic fibroblast cell line were treated with increasing concentrations of 17-AAG for 4 days, and the effect on cell growth was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The 50% inhibitory concentration (IC50) of all glioma cell lines ranged from 0.05 to 0.5 μM 17-AAG, as compared to 1.5 μM for the nontumorigenic cells.	18682579

In vivo

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:^[1]	- Collapse Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 5 days Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 Dosages: ~50 mg/kg Administration: Injection i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (170.73 mM)
	Water	Insoluble
	Ethanol	'5 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+corn oil For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tanespimycin (17-AAG) SDF

Molecular Weight	585.69
Formula	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	CP127374,NSC-330507, KOS 953
Smiles	COC1CC(C)CC2=C(NCC=C)C(=O)C=C(NC(=O)C(=C\C=C/C(OC)C(OC(N)=O)/C(=C/C(C)C1O)C)\C)C2=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00103272	Terminated	Drug: tanespimycin\|Drug: bortezomib	Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00098488	Terminated	Drug: tanespimycin\|Biological: rituximab	B-cell Chronic Lymphocytic Leukemia\|Prolymphocytic Leukemia\|Refractory Chronic Lymphocytic Leukemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00118248	Completed	Drug: tanespimycin	Recurrent Thyroid Cancer\|Stage IV Follicular Thyroid Cancer\|Stage IV Papillary Thyroid Cancer\|Thyroid Gland Medullary Carcinoma	National Cancer Institute (NCI)	December 2004	Phase 2
NCT00098423	Completed	Drug: tanespimycin\|Drug: cytarabine	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Blastic Phase Chronic Myelogenous Leukemia\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndromes\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Anemia With Excess Blasts in Transformation\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes	National Cancer Institute (NCI)	November 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
Answer:
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90. VER155008 inhibits autophagy and causes reduced levels of HSP90 client proteins.
Luminespib (NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth inhibition, autophagy and apoptosis. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association. Geldanamycin attenuates virus infection-induced ALI (acute lung injury)/ARDS (acute respiratory distress syndrome) by reducing the host's inflammatory responses.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM. NVP-HSP990 induces cell cycle arrest and apoptosis.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)